---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-030143"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:57:30.368012+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# UroGen acquires ICVB-1042 assets from IconOVir for shares, milestone, and royalties

## Summary
- UroGen issued 374,843 ordinary shares (worth $4.0M) to IconOVir as upfront consideration.
- UroGen agreed to pay $15.0M cash milestone on cumulative global net sales of ICVB-1042 products.
- UroGen will pay low single-digit royalties on worldwide net sales of ICVB Products.
- Entities affiliated with Chair Arie Belldegrun hold promissory notes entitling them to ~28.3% of purchase price.

## SEC filing metadata
- accession: 0001193125-25-030143
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312525030143/0001193125-25-030143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312525030143/d897858d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-030143
- JSON: https://secwatch.observer/filing/0001193125-25-030143.json
- Plain text: https://secwatch.observer/filing/0001193125-25-030143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.